1363. Preliminary Safety Results from a Phase 1 First in Human Study of VYD222: an Extended Half-Life Monoclonal Antibody (mAb) in Development for COVID-19 Prevention

BACKGROUND: VYD222 is a fully human IgG1 mAb demonstrating broad and potent in vitro neutralizing activity across SARS-CoV-2 variants including XBB.1.5. VYD222 is a re-engineered version of adintrevimab, an Fc-modified mAb that has a robust safety data package and demonstrated clinically meaningful...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahoney, Kathryn, Gupta, Deepali, Li, Yong, Betancourt, Natalia, Das, Aanika, Campanaro, Ed, Schmidt, Pete
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678193/
http://dx.doi.org/10.1093/ofid/ofad500.1200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678193/
http://dx.doi.org/10.1093/ofid/ofad500.1200

Ejemplares similares